Clinical trial · Interventional
A Study of LY3200882 in Participants With Solid Tumors
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
NCT02937272CI-TRIAL-00107254active not recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Intensity Modulated Radiotherapy | Radiation | — | UNRESOLVED |
| LY3200882 | Drug | — | UNRESOLVED |
| LY3300054 | Drug | — | UNRESOLVED |
| nab-Paclitaxel | Drug | Nab-paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (8)
- type
- EXPERIMENTAL
- label
- LY3200882 Schedule 1 Escalation
- interventionNames
- Drug: LY3200882
- type
- EXPERIMENTAL
- label
- LY3200882 Schedule 2 Escalation
- interventionNames
- Drug: LY3200882
- type
- EXPERIMENTAL
- label
- LY3200882 Schedule 1 Expansion
- interventionNames
- Drug: LY3200882
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The participant must have histological or cytological evidence of cancer. * Have adequate organ function. * Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. * Are able to swallow capsules and tablets. Exclusion Criteria: * Have moderate or severe cardiovascular disease. * Have a serious concomitant systemic disorder. * Have acute leukemia.
References
Publications (1)
- DERIVEDYap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. Epub 2021 Sep 21. PMID 34548321